OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lessened its stake in OptiNose, Inc. (NASDAQ:OPTN) by 93.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 333,333 shares of the company’s stock after selling 4,666,667 shares during the quarter. D. E. Shaw & Co. Inc. owned about 3.31% of OptiNose worth $2,227,000 at the end of the most recent reporting period.

Separately, Acorn Capital Advisors LLC purchased a new position in OptiNose in the 4th quarter worth approximately $2,824,000. 85.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

OPTN has been the subject of several research analyst reports. Lake Street Capital cut OptiNose from a “buy” rating to a “hold” rating and reduced their target price for the company from $17.00 to $9.00 in a research note on Thursday, March 20th. Piper Sandler reiterated a “neutral” rating and issued a $9.00 target price (down from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, HC Wainwright restated a “neutral” rating and set a $9.00 price objective on shares of OptiNose in a research note on Monday.

OptiNose Stock Down 1.1%

NASDAQ:OPTN opened at $9.60 on Wednesday. The business’s 50-day moving average price is $8.89 and its 200 day moving average price is $7.42. The firm has a market cap of $97.22 million, a P/E ratio of -2.29 and a beta of -0.88. OptiNose, Inc. has a 52-week low of $4.82 and a 52-week high of $20.03.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.27). The company had revenue of $18.51 million during the quarter, compared to analysts’ expectations of $17.70 million. Sell-side analysts expect that OptiNose, Inc. will post -3.22 EPS for the current year.

Insider Buying and Selling

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the completion of the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at approximately $671,464.99. This trade represents a 4.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is owned by corporate insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.